Introducing Revvity – Expanding the boundaries of human potential through science.
All products and services previously affiliated with Oxford Immunotec are now part of Revvity.

Oxford Immunotec to Present at the UBS Global Healthcare Conference

OXFORD, United Kingdom and MARLBOROUGH, Mass., May 14, 2019 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the UBS Global Healthcare Conference on Tuesday, May 21, 2019, at 3:30 p.m. EDT. The conference will be held at the Grand Hyatt New York in New York, NY.

About Oxford Immunotec 

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary assays for immunology and infectious disease. The Company’s T-SPOT®.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

CONTACTS:

For Media and Investor Inquiries:
Matt McLaughlin
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
mtmclaughlin@oxfordimmunotec.com